AstraZeneca has eliminated approximately 600 sales positions within its U.S. respiratory and immunology commercial divisions. This significant workforce reduction is part of a broader initiative to achieve $1.5 billion in annual cost savings by 2029. While some affected employees may be reassigned internally, the cuts are linked to the underperformance of certain asthma medications. The company is reallocating resources to pipeline growth as part of this restructuring. This move signals a strategic shift in the pharmaceutical giant's operational focus.
United States
https://www.fiercepharma.com/pharma/astrazeneca-cuts-600-us-sales-jobs-amid-15b-savings-plan-bloomberg